2 Einträge |
Seite 1 / 1
![]() |
403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS. |
Steger GG, Dominguez A, Switsers O, Dobrovolskaya N, Giotta F, Glogowska I, Tubiana-Mathieu N, Pecherstorfer M, Ardizzoia A, Bougnoux P, Blasinska-Morawiec M, Veyret C, Garcia S, Dorca J, Marth C, Manikhas A, Benasso M, Protsenko S, Villanova GR, Espinosa E |
Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 7. pii: 2241150. doi: 10.1093/annonc/mdu329.52 |
PMID: 28172231 |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
2 Einträge |
Seite 1 / 1
![]() |